title: The efficacy of HSV-2 vaccines based on gD and gB is enhanced by the addition of ICP27.
abstract: DNA vaccines expressing HSV-2 gD, gB, ICP27, VP22 and VP13/14 were shown to be immunogenic in mice; gD and gB elicited neutralising antibody, and all five antigens induced T cell responses measured by IFNγ ELISPOT. In murine HSV-2 challenge studies, gD and gB provided moderate to high levels of protection while ICP27 provided a lower level of protection depending on the model (intravaginal or intranasal) and the challenge dose. Combining vaccines expressing gB or gD with vaccines expressing ICP27 provided greater protection than any antigen alone. We conclude that the addition of ICP27 to enhance the anti-viral T cell response can improve the efficacy of gD- and gB-based vaccines.
authors.affiliation: Pfizer PGRD, Sandwich, Kent CT13 9NJ, UK.
authors.forename: Helen
authors.initials: H
authors.lastname: Bright
authors.forename: David Lucia
authors.initials: DL
authors.lastname: Perez
authors.forename: Clare
authors.initials: C
authors.lastname: Christy
authors.forename: Paul
authors.initials: P
authors.lastname: Cockle
authors.forename: Jim E
authors.initials: JE
authors.lastname: Eyles
authors.forename: Daisy
authors.initials: D
authors.lastname: Hammond
authors.forename: Tansi
authors.initials: T
authors.lastname: Khodai
authors.forename: Susanne
authors.initials: S
authors.lastname: Lang
authors.forename: Kate
authors.initials: K
authors.lastname: West
authors.forename: Peter T
authors.initials: PT
authors.lastname: Loudon
mesh_terms: D000818:Animals; D000914:Antibodies, Viral / Q000097:blood; D004195:Disease Models, Animal; D005260:Female; D006566:Herpesviridae Infections / Q000276:immunology / Q000473:pathology / Q000517:prevention & control*; D018258:Herpesvirus 2, Human / Q000235:genetics / Q000276:immunology*; D022283:Herpesvirus Vaccines / Q000008:administration & dosage / Q000276:immunology*; D017874:Immediate-Early Proteins / Q000235:genetics / Q000276:immunology*; D051379:Mice; D008807:Mice, Inbred BALB C; D012720:Severity of Illness Index; D013601:T-Lymphocytes / Q000276:immunology; D019444:Vaccines, DNA / Q000008:administration & dosage / Q000276:immunology*; D014759:Viral Envelope Proteins / Q000235:genetics / Q000276:immunology*; D014764:Viral Proteins / Q000235:genetics / Q000276:immunology*
chemical_list: D000914:Antibodies, Viral; D022283:Herpesvirus Vaccines; D017874:Immediate-Early Proteins; C558833:UL54 protein, herpes simplex virus type II; D019444:Vaccines, DNA; D014759:Viral Envelope Proteins; D014764:Viral Proteins; C044525:glycoprotein B, herpes simplex virus type 2; C040570:glycoprotein D-herpes simplex virus type 2